GC Cell's 'Immuncell LC Injection' Licensed to Indonesia

GC Cell announced on the 10th that it has signed a technology transfer and license-out agreement for Immuncell-LC Injection with Bifarma, an Indonesian stem cell therapy company, following the strategic partnership established in June.

[Photo by GCell]

Bifarma is a subsidiary of PT Kalbe Farma Tbk, one of the largest pharmaceutical groups in Southeast Asia. It possesses Indonesia's first Good Manufacturing Practice (GMP) certified cell therapy manufacturing facility and has capabilities in cold chain distribution and oncology-focused sales and marketing within the country, making it an ideal partner for the local commercialization of Immuncell-LC Injection.

The total contract value for this technology transfer targeting Indonesia is approximately 16 billion KRW. Following the product launch next year, GC Cell expects to receive double-digit royalties linked to sales revenue. Detailed terms have been kept confidential by mutual agreement.

James Park, CEO of GC Cell, stated, “We will begin the technology transfer simultaneously with the signing of this license agreement and aim to launch next year based on domestic approval data. This contract will be a very important milestone for Immuncell-LC Injection to expand into the global market and provide new treatment options to more patients.”

This content was produced with the assistance of AI translation services.